Rockville, Md. (September 12, 2023) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, today announced the United States Patent and Trademark Office (USPTO) issued a patent, entitled Materials and Methods for Producing Blood Products (US Patent 11,752,468 B2 ('468 Patent) covering the technology used to produce Freeze-dried Platelet-derived Hemostat (FPH) Drug Substance, Thrombosomes®, used in our Phase II clinical trials as well as unique product attributes. Thrombosomes are a novel, shelf-stable hemostatic agent currently in Phase II clinical trials.
According to Keith Moskowitz, VP of Discovery Research, “the ‘468 patent is the third issued patent in the US for Cellphire Therapeutics’ FPH core technologies allowing expanded manufacturing, product claims, and coverage through 2043.” The issuance of this patent exemplifies Cellphire Therapeutics’ emphasis on innovation and its ability to both generate and issue Intellectual Property relevant for the commercialization of the Freeze-dried Platelet-derived Hemostat (FPH) Technology. Cellphire anticipates further allowances in this and other patent families both in the US and worldwide later in 2023 and 2024.
"This is an important milestone for the company on the road to achieving our mission of saving lives with our cellular therapeutics,” said Mike Gaffney, Cellphire Therapeutics CEO. “We appreciate and thank our collaborators, federal funding agencies, and our team for helping us realize this achievement.”
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications for Orphan populations to surgical, trauma, traumatic brain injury (TBI) and intercranial hemorrhage (ICH) unmet clinical needs, among other things. For more information, visit www.cellphire.com.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021C.
Media and Investor Relations:
Vice President, Business Operations